This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (= 89) or PD-L1 (atezolizumab) (= 69) inhibitors at the Virgen del Roco Hospital in Seville. or recurrent NSCLC who received PD-1 (nivolumab) (= 89) or PD-L1 (atezolizumab) (= 69) inhibitors at the Virgen del Roco Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (= 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55C1.17, = 0.260; OS HR: 0.79, 95% CI: 0.52C1.21, = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) ( 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab. (%)(%)= 89) or atezolizumab (= 69) as a second- or third-line treatment were enrolled in the study. The clinicopathological characteristics of all the patients are described in Table 2. The median age at the beginning of ICI treatment was 64 years (range 37C86). It was significantly higher in patients treated with nivolumab (= 0.005). The majority of patients were male (78.5%), and only 15.2% had an ECOG-PS greater than or equal to two. For the whole cohort, a similar distribution pattern represented by histological subtype was represented. However, this distribution varied significantly according to immunotherapy type, and there were more patients with squamous histology in the nivolumab group ( 0.001). Baseline CNS metastases were found in 16.5% of the patients, with 1-Naphthyl PP1 hydrochloride a significant difference between the nivolumab and atezolizumab groups (= 0.044). There were more patients with analysed PD-L1 expression in the atezolizumab than in the nivolumab group ( 0.001). Most patients were current smokers or had quit smoking less than 10 years ago (73.4%). There were more patients who received ICI as the second-line of treatment (79.1%) and who were previously treated with platinum-based therapies (94.9%). The median length of follow-up for the entire cohort was 8.32 months (95% CI: 0.10C46.95). On the other hand, Table S1 shows the baseline characteristics of the patients grouped by histological type; in this case, the age was significantly higher in the squamous group ( 0.001), as well as the presence of LTBP1 COPD (= 0.041), while the presence of CNS metastasis was significantly higher in the nonsquamous group (= 0.004). Table 2 Baseline characteristics by treatment group. (%)= 158)= 89)= 69)Valuevalue for Students t test, * value for chi-squared test, ? value for Fishers exact test, value for MannCWhitney U test. ICI, Immune Checkpoint Inhibitor; ECOG, Eastern 1-Naphthyl PP1 hydrochloride Cooperative Oncology Group; CNS, central nervous system; COPD, Chronic Obstructive Pulmonary Disease; CI, confidence interval; mo, months. By the end of the study, 110 patients (69.6%) died, 64 (71.9%) were included in the nivolumab group and 46 (66.7%) were included in the atezolizumab group. After ICI discontinuation (Table 3), 62 (39.24%) patients received conventional chemotherapy, and one patient received TKI (erlotinib) therapy. There was no difference in the administration of the subsequent treatment between the two groups. Vinorelbine and docetaxel were the most commonly used subsequent treatments, 14.6% and 13.9%, respectively. Table 3 Summary of systemic brokers received following immunotherapy discontinuation. (%)= 158)= 89)= 69)= 0.140) and DCR (49.4% vs. 36.2%, = 0.113). Response could not be assessed in one patient in the atezolizumab group. Table 4 Best response to treatment. = 158)= 89)= 69)Valuevalue for chi-squared test; ORR, Objective Response Rate; DCR, Disease Control Rate; CI, confidence interval. 2.3. Survival Outcomes For the whole cohort (Physique 1), the median PFS and OS values were 3.19 months (95% CI: 2.31C4.06) and 9.03 months (95% CI: 6.60C11.47), respectively. The estimated rate of PFS was 37.1% at 6 months and 27.1% at 12 1-Naphthyl PP1 hydrochloride months. For OS, the estimated rate was 41.9% at 12 months, 27.5% at 24 months and 15.9% at 36 months. The median PFS for patients treated with nivolumab was 3.55 months (95% CI: 1.66C5.44), while the median PFS for those treated with atezolizumab was 2.89 months (95% CI: 1.84C3.94) (Physique 2A). The median OS in the patients treated with nivolumab and atezolizumab was 9.03 (95% CI: 5.51C12.56) and 9.00 (95% CI: 6.00C12.00), respectively (Determine 2B). There were no significant differences in either PFS.
This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (= 89) or PD-L1 (atezolizumab) (= 69) inhibitors at the Virgen del Roco Hospital in Seville
